Hospira 10-Q 28 Apr 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 24, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	HOSPIRA INC
Entity Central Index Key	1274057
Document Type	10-Q
Document Period End Date	31-Mar-15
Amendment Flag	FALSE
Current Fiscal Year End Date	-19
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		172,778,850
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Unaudited) (USD $)	3 Months Ended
In Millions, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net sales	$1,174.90	$1,050.80
Cost of products sold	651.4	681.2
Restructuring and impairment	31.1	0.7
Research and development	135.4	83.2
Selling, general and administrative	223.6	186.1
Total operating costs and expenses	1,041.50	951.2
Income From Operations	133.4	99.6
Interest expense	15	20.5
Other income, net	-3.5	-2
Income Before Income Taxes	121.9	81.1
Income tax expense	47.9	16.5
Undistributed equity income from affiliates	-1.6	-3.3
Net Income	75.6	67.9
Earnings Per Common Share:
Basic (in dollars per share)	$0.44	$0.41
Diluted (in dollars per share)	$0.43	$0.40
Weighted Average Common Shares Outstanding:
Basic (in shares)	171.4	166.5
Diluted (in shares)	175.1	168.4
Statements of Comprehensive Income:
Foreign currency translation adjustments, net of taxes of $0.0 for all periods	-67.7	28.7
Pension liability adjustments, net of taxes of $(1.0) and $(1.5), respectively	3.9	1.7
Unrealized gains (losses) on investments, net of taxes of $(1.2) and $0.0, respectively	1.5	-0.4
Cash flow hedge adjustments, net of taxes of $0.0 for all periods	0.1	0
Other Comprehensive (Loss) Income	-62.2	30
Net Income	75.6	67.9
Comprehensive Income	$13.40	$97.90

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Income and Comprehensive Income (Parenthetical) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Foreign currency translation adjustments, taxes	$0	$0
Pension liability adjustments, taxes	-1	-1.5
Unrealized (losses) gains on marketable equity securities, taxes	1.2	0
Reclassification of gains on terminated cash flow hedges, taxes	$0	$0

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash Flow From Operating Activities:
Net Income	$75.60	$67.90
Adjustments to reconcile Net Income to net cash from operating activities-
Depreciation	49.2	43.9
Amortization of intangible assets	11.9	21.8
Stock-based compensation expense	14.1	11
Undistributed equity income from affiliates	-1.6	-3.3
Deferred income taxes and other tax adjustments	6.7	12.9
Impairments and other asset charges	1.8	0
Changes in assets and liabilities, net of the effects of acquisitions-
Trade receivables	-16.9	20.4
Inventories	-76	-70.4
Prepaid expenses and other assets	9.2	-32.9
Trade accounts payable	-48	20.2
Other liabilities	-134.4	-78.8
Other, net	8.1	5.6
Net Cash (Used in) Provided by Operating Activities	-100.3	18.3
Cash Flow From Investing Activities:
Capital expenditures (including instruments placed with or leased to customers)	-103.4	-95.1
Acquisitions, net of cash acquired	0	-9
Purchases of intangibles and other investments	-18.4	-3.1
Proceeds from disposal of businesses and assets	0	2.9
Net Cash Used in Investing Activities	-121.8	-104.3
Cash Flow From Financing Activities:
Other borrowings, net	-1.2	-62.2
Excess tax benefit from stock-based compensation arrangements	33.3	0.7
Proceeds from stock options exercised less taxes paid related to net share settlements of $27.7 and $4.9, respectively	43.1	25.2
Net Cash Provided by (Used in) Financing Activities	75.2	-36.3
Effect of exchange rate changes on cash and cash equivalents	-11.8	1.3
Net change in cash and cash equivalents	-158.7	-121
Cash and cash equivalents at beginning of period	802.4
Cash and cash equivalents at end of period	643.7
Supplemental Cash Flow Information:
Interest	50.8	50.5
Income taxes, net of refunds	4.4	4.9
Accrued capital expenditures	$37.50	$23

Condensed_Consolidated_Stateme3

Condensed Consolidated Statements of Cash Flows (Unaudited) Condensed Consolidated Statements of Cash Flows (Parenthetical) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Taxes paid related to net share settlements	$27.70	$4.90

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Unaudited) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Current Assets:
Cash and cash equivalents	$643.70	$802.40
Trade receivables, less allowances of $9.3 and $9.6, respectively	595.8	601.9
Inventories, net	1,181	1,133.30
Deferred income taxes and other	190.7	230
Prepaid expenses	64	69.3
Other receivables	113.2	117.3
Total Current Assets	2,788.40	2,954.20
Property and equipment, net	1,852.70	1,816.70
Intangible assets, net	126.4	123.4
Goodwill	1,083.90	1,089.10
Deferred income taxes	312.9	295.4
Investments	257.2	252.2
Other assets	128.1	119
Total Assets	6,549.60	6,650
Current Liabilities:
Short-term borrowings	4.8	6.8
Trade accounts payable	359.6	414.5
Salaries, wages and commissions	162.8	252
Other accrued liabilities	597.1	626.8
Total Current Liabilities	1,124.30	1,300.10
Long-term debt	1,754.20	1,749.20
Deferred income taxes	4.5	5.4
Post-retirement obligations and other long-term liabilities	230	258.7
Commitments and Contingencies
Total Shareholders' Equity	3,436.60	3,336.60
Total Liabilities and Shareholders' Equity	$6,549.60	$6,650

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Statement of Financial Position [Abstract]
Trade receivables, allowances	$9.30	$9.60

Condensed_Consolidated_Stateme4

Condensed Consolidated Statement of Changes in Shareholders' Equity (USD $)	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Loss
In Millions, unless otherwise specified
Balances at Dec. 31, 2014	$3,336.60	$1.80	($599.80)	$2,044.50	$2,257	($366.90)
Common stock outstanding (shares)	172.6
Increase (Decrease) in Shareholders' Equity
Net Income	75.6
Other comprehensive loss	-62.2	0	0	0	0	-62.2
Changes in shareholders' equity related to incentive stock programs	86.6	0	0	86.6	0	0
Changes in shareholders' equity related to insentive stock programs (in shares)		2.2
Balances at Mar. 31, 2015	$3,436.60	$1.80	($599.80)	$2,131.10	$2,332.60	($429.10)
Balances (in shares) at Mar. 31, 2015		172.6

Basis_of_Presentation_and_Sign

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2015
Basis of Presentation and Significant Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies
	Description of Business
	Hospira, Inc. is a leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars all of which it develops, manufactures, markets and distributes. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. Hospira's portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and Medication Management products. Hospira's broad portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities.
	Hospira conducts operations worldwide and is managed in three reportable segments: Americas; Europe, Middle East and Africa; and Asia Pacific. See Note 25 for further information.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission for interim reporting and, therefore, do not include all information and footnote disclosures normally included in audited financial statements prepared in conformity with GAAP. However, in the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary to present fairly the results of operations, financial position and cash flows have been made. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the 2014 Form 10-K. The results of operations for any interim period are not necessarily indicative of the results of operations to be expected for the full year.
	New Accounting Standards
	Hospira is currently evaluating the impact of the following standards on its consolidated financial statements and related disclosures:
	Standard	Description	Effective date of the standard
	ASU 2014-09, Revenue from Contracts with Customers	Supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of the standard is to recognize revenues to depict the transfer of promised goods or services to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The standard defines a five step process to achieve this core principle.	Annual reporting periods beginning after December 15, 2016. Early adoption is not permitted.
			In April 2015, the Financial Accounting Standards Board issued a proposed ASU for a one-year deferral of the effective date of the new revenue recognition standard. If approved, the new standard will become effective for the annual reporting period (including interim periods within those periods) beginning after December 15, 2017 and can be adopted either retrospectively to each prior reporting period presented or as a cumulative effect adjustment as of the date of adoption.
	ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs	Changes the presentation of debt issuance costs in financial statements where an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense.	For fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015.
		Hospira's debt issuance costs, net of amortization, as of March 31, 2015 were $13.5 million reported as Other assets.
	For more information on Hospira's accounting standards that were recently adopted, see "Part II, Item 8. Financial Statements and Supplementary Data, Note 1," in Hospira's 2014 Form 10-K.
	Significant Accounting Policies
	The following information updates the description of significant accounting policies contained in Note 1 to Hospira's consolidated financial statements included in Hospira's 2014 Form 10-K.
	Supplier Advances
	Hospira periodically makes supplier advances to achieve timely procurement of products or product components. Supplier advances are in some cases long-term, refundable under certain conditions, either interest bearing or interest free, primarily unsecured and subject to credit risk. In estimating an allowance for loss, Hospira monitors supplier credit, among other factors, and recognizes an allowance in the Condensed Consolidated Statements of Income based on the nature of the advance. Total supplier advances were $33.4 million and $50.9 million as of March 31, 2015 and December 31, 2014, respectively. The current and long-term balances are reported in Prepaid expenses and Other assets, respectively, in the Condensed Consolidated Balance Sheets.
	Unapproved Products
	Prior to regulatory approval and launch Hospira capitalizes costs associated with certain products. Hospira capitalizes product costs, material and conversion costs in preparation for product launches prior to regulatory approval when regulatory approval of the products is considered probable. Unapproved product inventories were $52.7 million and $52.5 million as of March 31, 2015 and December 31, 2014, respectively, and the current and long-term portions are reported in Prepaid expenses and Other assets, respectively, in the Condensed Consolidated Balance Sheets. Unapproved product reserves were $6.8 million and $7.6 million as of March 31, 2015 and December 31, 2014, respectively.

Business_Acquisition

Business Acquisition	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Acquisition	Business Acquisitions
	Orchid (Penem and Penicillin Active Pharmaceutical Ingredient Business and Associated Research and Development Facility)
	On July 4, 2014, Hospira, through its wholly-owned subsidiary, Hospira Healthcare India Private Limited, acquired from Orchid its penem and penicillin API business located in Aurangabad, India, and associated research and development facility based in Chennai, India, along with the related assets and employees associated with these operations, for a preliminary purchase price of $247.2 million, subject to certain adjustments. A portion of the purchase price, $17.0 million, is subject to an eighteen month hold-back. Pursuant to the terms of the purchase agreement, some or all of such hold-back amount may ultimately be retained by Hospira.
	During the three months ended March 31, 2015 and 2014, Hospira incurred $0.5 million and $0.9 million, respectively, of acquisition and integration-related costs, reported in Selling, general and administrative. Cumulative acquisition and integration-related costs as of March 31, 2015 were $40.1 million.
	The assets acquired and liabilities assumed at their respective estimated fair values is preliminary and based on the initial measurements as of the acquisition date of July 4, 2014. The fair value of certain acquired liabilities and tax related items is pending finalization of the valuation, which may result in significant adjustments, and will be completed as soon as practicable. The following table summarizes the fair value of the assets acquired and liabilities assumed, based on management's best estimate:
	(dollars in millions)
	Current assets, net	$	57.1
	Property and equipment	120.1
	Intangible assets (product rights)	24.6
	IPR&D	3.7
	Goodwill	48.7
	Other non-current assets and liabilities, net	(7.0		)
	Total allocation of purchase price	$	247.2
	Intangible assets (product rights) have an estimated weighted average useful life of 9 years. IPR&D is considered an indefinite-lived intangible asset. Goodwill, primarily assigned to the Americas reportable segment, includes the expected synergies and other benefits that Hospira believes will result from the integrated operations. Goodwill is not expected to be deductible for tax purposes.
	Evolabis
	In February 2014, Hospira acquired a Brazilian-based oncology distributor, Evolabis Produtos Farmacêuticos Ltda., adding approximately 15 on-market oncology products to Hospira's portfolio in Brazil, accelerating expansion of its injectable pharmaceutical product line.
	The operating results of the acquisitions (Orchid and Evolabis) have been included in Hospira's results of operations since the individual acquisition dates, and pro forma results of operations for these acquisitions (Orchid and Evolabis) have not been presented as they are not material to Hospira's results of operations, either individually or in the aggregate.

Restructuring_Actions

Restructuring Actions	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Restructuring Actions	Restructuring and Optimization Actions
	Hospira aims to achieve a culture of continuous improvement to enhance its efficiency, effectiveness and competitiveness and improve its cost base. As part of this strategy, Hospira has taken a number of actions to reduce operating costs and/or optimize operations. The net charges related to these actions consist primarily of severance and other employee benefits, other exit costs, other asset (inventory) charges, impairments, accelerated depreciation, contract termination costs and gains or losses on disposal of assets and/or product lines.
	Facilities Optimization
	In March 2015, Hospira initiated a plan to discontinue API R&D related activities at its Boulder, Colorado manufacturing facility. For the three months ended March 31, 2015, Hospira incurred $0.7 million of employee related and other exit costs and $1.8 million of asset impairments reported in Restructuring and impairment.
	In January 2015, Hospira announced a plan for the closure, in the second half of 2015, of its Clayton, North Carolina manufacturing facility. The closure will include the discontinuation or transfer of the products manufactured at the site to other Hospira locations or third parties. Hospira estimates that this activity will result in total charges of approximately $45 million, including an impairment charge in the Americas segment of $21.9 million reported in Restructuring and impairment for the year ended December 31, 2014, and charges expected to be recognized through 2015 that are estimated to include: (i) approximately $15 million of cash for employee-related costs, including costs for severance, retention, and other employee related assistance and other exit costs associated with the plan; and (ii) approximately $8 million in other non-cash costs, including accelerated depreciation of plant assets. The cash related charges do not include capital expenditures or product transfer costs related to establishing manufacturing operations in any other locations or offset from any potential proceeds from the sale of the existing facility and related assets. For the three months ended March 31, 2015, Hospira incurred charges of $10.4 million reported in Restructuring and impairment.
	Restructuring
	Starting in late 2012 and continuing through 2015, Hospira incurred costs to optimize commercial organizational structures, and related functions, in all segments. As Hospira continues to optimize its global commercial operations and related functions and align investments to support future growth, Hospira anticipates that similar restructuring actions may continue through 2015. The costs are reported in Restructuring and impairment and primarily include aggregate severance charges of $15.9 million and contract termination charges of $2.3 million. Of the aggregate costs, $0.6 million and $0.3 million were incurred in the three months ended March 31, 2015 and 2014, respectively.
	The following summarizes the aggregate facility optimization and restructuring activity including Device Strategy related restructuring charges, see Note 4, for the three months ended March 31, 2015:
	(dollars in millions)	Employee-Related			Impairment and Accelerated Depreciation Charges			Other		Total
		Benefit Costs
	Balance at January 1, 2015	$	2.8		$	—		$	0.5	$	3.3
	Costs incurred	23.7			5.9			1.5		31.1
	Payments	(1.1		)	—			—		(1.1		)
	Non-cash items	—			(5.9		)	—		(5.9		)
	Balance at March 31, 2015	$	25.4		$	—		$	2	$	27.4

Device_Strategy

Device Strategy	3 Months Ended
	Mar. 31, 2015
Device Strategy [Abstract]
Device Strategy	Device Strategy
	Hospira continues to implement its Device Strategy announced in May 2013, an initiative intended to establish a streamlined and modernized product portfolio addressing customer needs and positioning Hospira for future innovation and growth, while supporting continued advancement of device remediation, including device quality improvement efforts. The Device Strategy is expected to be predominantly completed by the end of 2015.
	In connection with the Device Strategy, that now includes the restructuring initiative described below, Hospira expects to incur future charges related to these actions. Hospira expects major cash costs to include the following: (i) customer sales allowances; (ii) customer accommodations, contract termination, and pump collection and destruction costs; (iii) pump retirement and replacement program administration, quality systems/process improvement, consulting costs and other costs; and (iv) severance and other employee related assistance and contract termination charges. Further, Hospira has incurred non-cash charges for various asset charges, primarily pump inventory charges, other pump-related asset impairments and accelerated depreciation on production equipment and Hospira-owned pumps in service.
	In January 2015, Hospira approved and initiated plans to streamline and optimize device manufacturing, research and development and service center activities in all segments, and the charges will be included as part of Device Strategy charges, as noted above.
	Charges incurred for the Device Strategy, primarily in the Americas segment, were reported as follows:
		Three Months Ended March 31,					Line Item in the
							Condensed Consolidated
	(dollars in millions)	2015			2014		Statement of Income
	Consulting, customer accommodations, contract termination, collection and destruction and other (releases) charges	$	(8.2	)	$	5.6	Cost of products sold
	Inventory (releases) charges	(0.3		)	0.3		Cost of products sold
	Severance and other related costs	17.6			—		Restructuring and impairment
	Other asset impairments and accelerated depreciation	—			0.4		Restructuring and impairment
	Total charges	$	9.1		$	6.3
	The amount, timing and recognition of additional charges associated with the Device Strategy will be affected by the nature of spending and the occurrence of commitments and triggering events, among other factors.
	See Note 3 and Note 16 for certain Device Strategy related and other accrual activity for the three months ended March 31, 2015.

Collaborative_Arrangements

Collaborative Arrangements	3 Months Ended
	Mar. 31, 2015
Collaborative Arrangements [Abstract]
Collaborative Arrangements	Collaborative and Other Arrangements
	On February 10, 2015, Hospira entered into a global collaboration agreement with Pfenex to develop and commercialize PF582, Pfenex’s biosimilar candidate for ranibizumab. Under the agreement, Hospira will be responsible for Phase III studies, manufacturing, regulatory approval, litigation, sales and marketing. Pfenex is responsible for completing Phase I and additional product characterization work. In March 2015, Hospira paid $51.0 million as an upfront milestone to Pfenex at the close of the agreement which is reported in Research and development expense for the three months ended March 31, 2015. Pfenex will be eligible to receive a combination of development milestone payments of approximately $31 million and sales-based milestone payments up to approximately $260 million, including tiered double-digit royalties on net sales of the product over the next five years and beyond under certain circumstances. Pfenex is obligated to contribute up to $20 million to fund a portion of the Phase III equivalence clinical trial costs.
	In December 2014, Hospira entered into a new agreement with Q Core. Under the agreement, Hospira will (i) license the rights to manufacture sets compatible with the Sapphire™ and SapphirePlus™ infusion pumps, (ii) provide milestone payments, some of which may be refundable, for new infusion pump products developed by Q Core in advance of or upon achievement of CE mark or FDA clearance and (iii) make advances to Q Core for the prepayment of inventory for new products. Under the agreement, Hospira will pay Q Core up to approximately $55 million primarily over the next two years or as milestones are achieved of which $17.8 million was paid and capitalized based on the nature of the assets in the three months ended March 31, 2015. Under the arrangement, new pump products are intended to be added to the portfolio that build upon the Sapphire™ platform and utilize Hospira MedNet™ safety software. The agreement includes the right for Hospira to acquire Q Core under certain conditions in the future, and the right to establish back-up manufacturing of Q Core pump products.
	On April 29, 2013, Hospira and NovaQuest entered into an arrangement for three biosimilar products: EPO (in the U.S. and Canada), filgrastim (in the U.S.) and pegylated filgrastim (globally). Hospira is responsible for research and development, regulatory approval, commercialization and distribution of these products. NovaQuest will contribute development funding up to $120.0 million, with contributions not exceeding $50.0 million in any single year and such amounts are recognized as an offset to Research and development expense as incurred as there is substantive and genuine risk of return of the investment inherent in these biosimilar development programs. In exchange for the development funding, if applicable, Hospira will make milestone payments to NovaQuest upon achieving the first commercial sale for each product of approximately $20 million, and such payments will be expensed to Cost of products sold as incurred. Hospira will also be required to pay NovaQuest royalties based upon commercial net sales of the products. In certain instances that result in the delay or failure of the products to be marketed (other than the failure of the products to achieve regulatory approval), Hospira may be obligated to make certain payments to NovaQuest as compensation for such unanticipated events. In these circumstances, reimbursement will be made in the form of royalties related to certain sales of Hospira's on-market products. Hospira's total payments to NovaQuest inclusive of the milestones and royalties are capped at a multiple of development funding, which in any reported period could be significant. For the three months ended March 31, 2015 and 2014, in connection with the NovaQuest agreement, Hospira recognized an offset to Research and development expense for development funding of $2.9 million and $6.9 million, respectively. Cumulative development funding recognized as an offset to Research and development expense from NovaQuest through the period ended March 31, 2015 was $90.9 million.
	For information on other Hospira collaborative and other arrangements, see "Part II, Item 8. Financial Statements and Supplementary Data, Note 1," in Hospira's 2014 Form 10-K.

Investments

Investments	3 Months Ended
	Mar. 31, 2015
Investments [Abstract]
Investments	Investments
	Investments, equity-method
	Hospira's equity-method investments primarily consist of a 50% ownership interest in a joint venture, Zydus Hospira Oncology Private Limited with Cadila. Equity income from affiliates, net, including the ZHOPL equity investment, was $1.6 million and $3.3 million for the three months ended March 31, 2015 and 2014, respectively. No distributions were received from ZHOPL for the three months ended March 31, 2015 and 2014.
	Combined income statement financial information of unconsolidated equity method investments is as follows:
		Three Months Ended March 31,
	(dollars in millions)	2015		2014
	Revenue	$	17.3	$	16.3
	Operating expenses	13.8		10.2
	Operating income	3.5		6.1
	Net Income	2.8		4.6
	Investments, at fair value
	As of March 31, 2015 and December 31, 2014, Investments, at fair value (available-for-sale marketable investments) included $2.7 million and $4.2 million of unrealized losses, respectively, which are included in Accumulated other comprehensive loss.
	On September 30, 2014, Hospira purchased a convertible bond from Celltrion Healthcare with an aggregate principal amount denominated in Korean Won equal to $200.0 million U.S. Dollars, due on September 30, 2019. Interest is payable quarterly at an annual rate of 6.0%. The convertible bond will be recognized as an available-for-sale investment and is subject to credit risk. Hospira may redeem some or all of the principal of the convertible bond for cash or an equity interest in Celltrion Healthcare, or, starting on the third anniversary of the issue of the convertible bond, the supply of biosimilar products. Additionally, Celltrion Healthcare may elect to pay interest on the convertible bond in cash, or in kind by providing biosimilar product to Hospira. Further, Hospira amended its co-exclusive agreement with Celltrion to amend commercial terms, which includes providing Hospira exclusive rights to specific biosimilar products in the U.S. and certain other territories.
	Investments, at cost
	In July 2014, Hospira advanced $30.0 million for an investment with a research and development venture with the potential obligation to invest an additional $15.0 million as early as 2015. In the initial phase of the agreement, the investment is fully refundable, subject to credit risk, to the extent certain development milestones are not met. The products developed are expected to provide Hospira commercialization opportunities in future periods.

Fair_Value_Measures

Fair Value Measures	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measures	Fair Value Measures
	The following table summarizes the basis used to measure certain assets and liabilities at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
				Fair Value Measurements at Reporting Date, Using:
		March 31,		Quoted Prices		Significant		Significant
				in Active Markets for		Other Observable		Unobservable
				Identical Items		Inputs		Inputs
	(dollars in millions)	2015		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency exchange contracts	$	11.4	$	11.4	$	—	$	—
	Investments	197		2.8		194.2		—
	Interest rate swap contracts	5.2		—		5.2		—
	Financial Liabilities:
	Foreign currency exchange contracts	3.3		—		3.3		—
				Fair Value Measurements at Reporting Date, Using:
		December 31,		Quoted Prices		Significant		Significant
				in Active Markets for		Other Observable		Unobservable
				Identical Items		Inputs		Inputs
	(dollars in millions)	2014		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency exchange contracts	$	3	$	3	$	—	$	—
	Investments	194.6		3.7		190.9		—
	Interest rate swap contracts	0.1		—		0.1		—
	Financial Liabilities:
	Foreign currency exchange contracts	0.6		—		0.6		—
	The fair value of the Level 1 assets is based on quoted market prices of the identical underlying security in an active market. The fair value of cash and cash equivalents, which include money market fund instruments, approximate their carrying value due to their short-term nature, and are within Level 1 of the fair value hierarchy. The fair value of the Level 2 assets and liabilities is primarily based on market observable inputs to quoted market prices, benchmark yields and broker/dealer quotes. Specific to the investment in Celltrion Healthcare, the inputs primarily used include South Korean benchmark interest rates adjusted for credit risk and foreign exchange rates. Level 3 inputs, as applicable, are unobservable inputs which reflect assumptions developed by management to measure assets and liabilities at fair value.
	The carrying values of certain financial instruments, primarily including accounts receivable, accounts payable and short-term borrowings, approximate their estimated fair values due to their short-term nature.
	The carrying value and estimated aggregate fair value, based primarily on market prices (Level 1), of the senior unsecured notes are as follows:
		March 31, 2015				December 31, 2014
	(dollars in millions)	Carrying		Fair Value		Carrying		Fair Value
		Value				Value
	Senior unsecured notes	$	1,750.00	$	2,038.90	$	1,750.00	$	1,924.00

Financial_Instruments_and_Deri

Financial Instruments and Derivatives	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Financial Instruments and Derivatives	Financial Instruments and Derivatives
	Hospira's operations are exposed to market risk primarily due to changes in currency exchange and interest rates. The objective in managing these risks is to reduce volatility on earnings and cash flows. To reduce the risk, Hospira enters into certain derivative financial instruments, when available on a cost-effective basis, to hedge its underlying economic exposure. For a more detailed description of Hospira's financial instruments and derivatives, see Note 8 to Hospira's consolidated financial statements included in Hospira's 2014 Form 10-K.
	The following table summarizes Hospira's fair value of outstanding derivatives:
		Condensed Consolidated Balance	March 31,			December 31,
	(dollars in millions)	Sheet Presentation	2015			2014
	Derivatives not designated as hedging instruments
	Foreign currency exchange contracts:	Other receivables	$	11.4		$	3
		Other accrued liabilities	3.3			0.6
	Derivatives designated as hedging instruments
	Interest rate swap contracts:	Other receivables	5.2			0.1
	The impact on earnings from derivatives activity was as follows:
		Line Item in the	Three Months Ended March 31,
		Condensed Consolidated
	(dollars in millions)	Statement of Income	2015			2014
	Derivatives not designated as hedging instruments
	Foreign currency exchange contracts	Other income, net	$	(5.0	)	$	(0.7	)
	Derivatives designated as hedging instruments
	Interest rate swap contracts	Interest income	(1.4		)	—

Inventories

Inventories	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories, net	Inventories, Net
	Inventories, net consist of the following:
		March 31,		December 31,
	(dollars in millions)	2015		2014
	Finished products	$	517.3	$	521.7
	Work in process	384.7		324.7
	Materials	279		286.9
	Total	$	1,181.00	$	1,133.30
	Inventory reserves were $126.0 million and $136.4 million as of March 31, 2015 and December 31, 2014, respectively.

Property_and_equipment_net

Property and equipment, net	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and equipment, net	Property and Equipment, Net
	Property and equipment, net consists of the following:
		March 31,			December 31,
	(dollars in millions)	2015			2014
	Property and equipment, at cost	$	3,651.80		$	3,607.20
	Accumulated depreciation	(1,799.1		)	(1,790.5		)
	Total Property and equipment, net	$	1,852.70		$	1,816.70

Goodwill_and_Intangible_assets

Goodwill and Intangible assets, net	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible assets, net	Goodwill and Intangible Assets, Net
	The following summarizes Goodwill and Intangible assets, net activity:
	(dollars in millions)	Goodwill			Intangible
					assets, net
	Balance at January 1, 2015	$	1,089.10		$	123.4
	Additions or adjustments	(2.2		)	16.7
	Amortization	—			(11.9		)
	Currency translation effect	(3.0		)	(1.8		)
	Balance at March 31, 2015	$	1,083.90		$	126.4
	Additions to Intangible assets, net are primarily related to the Americas reportable segment and the agreement with Q Core as discussed in Note 5.
	Intangible assets with definite lives are amortized on a straight-line basis over their estimated useful lives (1 to 12 years, weighted average 9 years). Indefinite lived intangibles, principally IPR&D, are not amortized until completion and regulatory approval. During the three months ended March 31, 2015 and 2014, intangible asset amortization expense was $11.9 million and $21.8 million, respectively, and reported in Cost of products sold.
	Intangible assets, net consist of the following:
		Gross Carrying Amount						Accumulated Amortization						Intangible assets, net
		March 31,			December 31,			March 31,			December 31,			March 31,		December 31,
	(dollars in millions)	2015			2014			2015			2014			2015		2014
	Product rights and other	$	542.4		$	554.3		$	(441.0	)	$	(457.8	)	$	101.4	$	96.5
	Customer relationships	7.2			7.4			(6.6		)	(6.4		)	0.6		1
	IPR&D	4.9			4.9			—			—			4.9		4.9
	Technology	39			39			(19.5		)	(18.0		)	19.5		21
	Total	$	593.5		$	605.6		$	(467.1	)	$	(482.2	)	$	126.4	$	123.4
	Intangible asset amortization for each of the five succeeding fiscal years is estimated at:
	Year	(dollars in millions)
	2015	$	44.9
	2016	24.1
	2017	17.2
	2018	7.8
	2019	5

Other_Assets

Other Assets	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Other assets	Other Assets
	Other assets consist of the following:
		March 31,		December 31,
	(dollars in millions)	2015		2014
	Supplier advances	$	28	$	25.5
	Net investment in sales-type leases, less current portion	4		6.5
	Unapproved products	36.6		36
	Non-current receivables	11		9.2
	All other	48.5		41.8
	Total	$	128.1	$	119

SalesType_Leases

Sales-Type Leases	3 Months Ended
	Mar. 31, 2015
Leases [Abstract]
Sales-Type Leases	Sales-Type Leases
	The net investment in sales-type leases of certain medication management products consists of the following:
			March 31,			December 31,
	(dollars in millions)		2015			2014
	Minimum lease payments receivables		$	10.6		$	13.7
	Unearned interest income		(0.8		)	(1.1		)
	Net investment in sales-type leases		9.8			12.6
	Current portion (1)		(5.8		)	(6.1		)
	Net investment in sales-type leases, less current portion (1)		$	4		$	6.5
	(1)	The current and long-term portions are reported in Trade receivables and Other assets, respectively.
	Hospira monitors the credit quality of sales-type leases and recognizes an allowance for credit loss based on historical loss experience. As of March 31, 2015 and December 31, 2014, allowance for credit losses and amounts past due 90 days for sales-type leases were not material.

Other_Accrued_Liabilities

Other Accrued Liabilities	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other Accrued Liabilities
	Other accrued liabilities consist of the following:
		March 31,		December 31,
	(dollars in millions)	2015		2014
	Accrued rebates	$	126	$	135.5
	Income taxes payable	13.1		3.5
	Product recalls, customer sales allowances, customer accommodations and other related accruals	126.1		127.5
	Accrued returns	26.8		29.1
	All other	305.1		331.2
	Total	$	597.1	$	626.8

PostRetirement_Obligations_and

Post-Retirement Obligations and Other Long-term Liabilities	3 Months Ended
	Mar. 31, 2015
Post-Retirement Obligations and Other Long-term Liabilities [Abstract]
Post-Retirement Obligations and Other Long-term Liabilities	Post-Retirement Obligations and Other Long-term Liabilities
	Post-retirement obligations and other long-term liabilities consist of the following:
		March 31,		December 31,
	(dollars in millions)	2015		2014
	Accrued post-retirement medical and dental costs	$	54.5	$	55.2
	Pension liabilities	88.9		91.9
	Unrecognized tax benefits, including penalties and interest	35.6		33.9
	Product recalls, customer sales allowances, customer accommodations and other related accruals	3.7		31.3
	Accrued returns	12.7		12.7
	All other	34.6		33.7
	Total	$	230	$	258.7

Product_Recalls_Customer_Sales

Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Product Recalls and Other Related Accruals	Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals
	The following summarizes Product recalls, customer sales allowances, customer accommodations and other related accruals activity for the three months ended March 31, 2015:
	(dollars in millions)	Product recalls, customer sales allowances, customer accommodations and other related accruals
	Balances at January 1, 2015	$	158.8
	Provisions net of releases of prior provisions	(11.2		)
	Payments	(17.8		)
	Balances at March 31, 2015	$	129.8

Pension_and_PostRetirement_Ben

Pension and Post-Retirement Benefits	3 Months Ended
	Mar. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Post-Retirement Benefits	Pension and Other Post-Retirement Benefits
	Retirement plans consist of defined benefit plans and legislated obligations such as pension plans, medical and dental plans and defined contribution plans. Plans cover certain employees both in and outside of the U.S.
	Net periodic benefit cost recognized for Hospira's pension and post-retirement medical and dental benefit plans consist of the following:
		Pension Plans
			Three Months Ended March 31,
	(dollars in millions)		2015			2014
	Service cost for benefits earned during the period		$	0.6		$	0.4
	Interest cost on projected benefit obligations		6.1			6.5
	Expected return on plans' assets		(7.5		)	(7.8		)
	Amortization of net actuarial losses		4.7			3.1
	Net periodic benefit cost		$	3.9		$	2.2
		Medical and Dental Plans
			Three Months Ended March 31,
	(dollars in millions)		2015			2014
	Interest cost on projected benefit obligations		$	0.6		$	0.6
	Amortization of net actuarial losses		0.2			0.1
	Net periodic benefit cost		$	0.8		$	0.7
	Hospira has no estimated minimum required contribution for 2015 to meet the funding rules of the Pension Protection Act of 2006, giving consideration to the Worker, Retiree, and Employer Recovery Act of 2008. While Hospira's funding policy requires contributions to its defined benefit plans equal to the amounts necessary to, at a minimum, satisfy the funding requirements as prescribed by Federal laws and regulations, Hospira also makes discretionary contributions when management deems it is prudent to do so. No contributions were made to the U.S. pension plan for the three months ended March 31, 2015.
	Certain Hospira employees in the U.S. and Puerto Rico participate in the Hospira 401(k) Retirement Savings Plan. For the three months ended March 31, 2015 and 2014, Hospira's expenses were $11.1 million and $11.6 million, respectively.

Shortterm_Borrowings_and_Longt

Short-term Borrowings and Long-term Debt	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Short-term Borrowings and Long-term Debt	Short-term Borrowings and Long-term Debt
	As of March 31, 2015, Hospira had a $1.0 billion unsecured revolving credit facility maturing in October 2016 with no amounts outstanding. Amounts borrowed under the Revolver, if any, and Hospira's debt and financial position may limit Hospira's availability for borrowings to less than $1.0 billion. As of March 31, 2015, Hospira had no limit on the availability under the Revolver.
	As of March 31, 2015, Hospira was in compliance with all financial covenants.
	For more information on Hospira's Senior Notes and other borrowings, interest rate swap contracts and the Revolver, see "Part II, Item 8. Financial Statements and Supplementary Data, Note 19," in Hospira's 2014 Form 10-K. There have been no material changes to the short-term borrowing or other debt arrangement information provided in Hospira's 2014 Form 10-K.

Income_Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes
	Taxes on income reflect the estimated annual effective rates, excluding the effect of significant unusual items. The effective tax rates are generally less than the statutory U.S. federal income tax rate principally due to the benefit of tax exemptions, of varying durations, in certain non-U.S. taxing jurisdictions.
	Hospira remains subject to tax examinations, which are in various stages, in the following major tax-paying jurisdictions: for years 2006 forward in Italy, for years 2007 forward in Australia, for years 2009 forward in Canada, for years 2010 forward in the U.S. and for years 2011 forward in the United Kingdom. Hospira estimates that within the next twelve months a decrease of up to approximately $10 million in the balance of unrecognized tax benefits could occur as a result of audit settlements or statute of limitations expirations.

Shareholders_Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2015
Stockholders' Equity Note [Abstract]
Shareholders' Equity	Shareholders' Equity
	Common Stock
	Hospira is authorized to issue 400.0 million shares of common stock, par value $0.01 per share, and 50.0 million shares of preferred stock, par value $0.01 per share. At March 31, 2015 and December 31, 2014, 185.8 million and 183.6 million common shares were issued, respectively, and 172.6 million and 170.4 million common shares were outstanding, respectively.
	Treasury Stock
	In April 2011, Hospira's Board of Directors authorized the repurchase of up to $1.0 billion of Hospira's common stock of which $800 million remains authorized taking into account prior repurchases. Hospira may periodically repurchase additional shares under this authorization, the timing of which will depend on various factors such as cash generation from operations, cash expenditure required for other purposes, current stock price and other factors. No common stock repurchases were made during the three months ended March 31, 2015. The Merger Agreement with Pfizer imposes certain restrictions upon repurchases of Hospira's common stock during the pendency of the Merger. See Note 26 for more information on the Merger Agreement with Pfizer.
	Dividends
	The Merger Agreement with Pfizer imposes certain restrictions upon Hospira's ability to pay dividends during the pendency of the Merger. See Note 26 for more information on the Merger Agreement with Pfizer.

Accumulated_Other_Comprehensiv

Accumulated Other Comprehensive (Loss), net of tax	3 Months Ended
	Mar. 31, 2015
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Accumulated Other Comprehensive Loss, net of tax	Accumulated Other Comprehensive Loss, Net of Tax
	Changes in Accumulated Other Comprehensive Loss, net of taxes consists of the following:
	(dollars in millions)		Cumulative Foreign Currency Translation Adjustments(1)			Cumulative Retirement Plans Unrealized Losses(2)			Cumulative Unrealized (Losses) on Investments(3)			Cumulative Losses on			Total Accumulated Other Comprehensive Loss
												Terminated Cash Flow Hedges(4)
	Balance at January 1, 2015		$	(228.8	)	$	(132.3	)	$	(4.2	)	$	(1.6	)	$	(366.9	)
	Other comprehensive (loss) income before reclassifications		(67.7		)	—			1.5			—			(66.2		)
	Amounts Reclassified from		—			3.9			—			0.1			4
	Accumulated Other Comprehensive Loss
	Balance at March 31, 2015		$	(296.5	)	$	(128.4	)	$	(2.7	)	$	(1.5	)	$	(429.1	)
	(1)	Net of taxes of $0.0 million as of March 31, 2015 and December 31, 2014.
	(2)	Net of taxes of $76.9 million and $77.9 million as of March 31, 2015 and December 31, 2014, respectively.
	(3)	Net of taxes of $2.2 million and $3.4 million as of March 31, 2015 and December 31, 2014, respectively.
	(4)	Net of taxes of $1.1 million as of March 31, 2015 and December 31, 2014.
	The following summarizes reclassifications out of Accumulated Other Comprehensive Loss:
			Three Months Ended March 31,
	(dollars in millions)		2015			2014			Line Item in the
									Condensed Consolidated
									Statement of Income
	Amortization of loss on terminated cash flow hedges		$	0.1		$	—		Other income, net
			—			—			Income tax expense
	Net of income taxes		0.1			—
	Amortization of pension plans actuarial losses		4.7			3.1			(1)
	Amortization of medical and dental plans actuarial losses		0.2			0.1			(1)
	Total amortization before income taxes		4.9			3.2
			(1.0		)	(1.5		)	Income tax expense
	Net of income taxes		3.9			1.7
	Total reclassifications for the period		$	4		$	1.7
	(1)	These Accumulated Other Comprehensive Loss components are included in the computation of net periodic benefit cost. See Note 17 for additional details.

Earnings_per_Share

Earnings per Share	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Earnings (Loss) per Share	Earnings Per Share
	Basic Earnings Per Share is computed by dividing Net Income by the number of weighted average common shares outstanding during the reporting period. Diluted Earnings Per Share is calculated to give effect to all potentially dilutive common shares that were outstanding during the reporting period, only in the periods in which such effect is dilutive. The following table shows the effect of stock-based awards on the weighted average number of shares outstanding used in calculating Diluted Earnings Per Share, and the number of shares excluded from the Diluted Earnings Per Share calculation as the exercise price of the awards exceeded the average stock price:
		Three Months Ended March 31,
	(shares in millions)	2015	2014
	Weighted average basic common shares outstanding	171.4	166.5
	Incremental shares outstanding related to stock-based awards	3.7	1.9
	Weighted average dilutive common shares outstanding	175.1	168.4
	Outstanding awards for which the exercise price of the award exceeds the average stock price	0.3	5.1

Incentive_Stock_Program

Incentive Stock Program	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Incentive Stock Program	Incentive Stock Program
	Hospira's 2004 Long-Term Stock Incentive Plan ("2004 Plan"), as amended, provides for the grant of shares of stock options, stock appreciation rights, stock awards (restricted stock, restricted stock units, performance shares and performance units) and cash-based awards to employees and non-employee directors. Stock-based compensation expense associated with Hospira's 2004 Plan consists of the following:
		Three Months Ended March 31,
	(dollars in millions)	2015			2014
	Stock-based compensation expense	$	14.1		$	11
	Income tax benefit recognized	5.1			4
	As of March 31, 2015, there was $118.5 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted average period of 1.9 years.
	Stock Options
	No options were granted in the three months ended March 31, 2015. For prior grants the weighted average grant date fair value using the Black-Scholes option-pricing model, and the corresponding weighted average assumptions were as follows:
		Three Months Ended March 31,
		2014
	Expected volatility	27.7		%
	Expected life (years)	4.7
	Risk-free interest rate	1.5		%
	Expected dividend yield	0		%
	Fair value per stock option	$	11.26
	Performance Share Awards
	No performance share awards were granted in the three months ended March 31, 2015. For prior grants the weighted average grant date fair value using the Monte Carlo simulation model and the corresponding weighted average assumptions were as follows:
		Three Months Ended March 31,
		2014
	Expected volatility	30.8		%
	Risk-free interest rate	0.6		%
	Expected dividend yield	0		%
	Fair value per performance share	$	54.55
	Restricted Stock and Units
	During the three months ended March 31, 2015, 0.8 million restricted stock and units were granted to certain employees and non-employee directors primarily as part of the 2015 annual grant. Hospira issues restricted stock and units that generally vest in approximately equal amounts on the first, second and third anniversaries of the grant date. The weighted average grant date fair value of restricted stock and units granted for the three months ended March 31, 2015 and 2014 was $87.51 and $42.74 per restricted award, respectively.

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2015
Loss Contingency, Information about Litigation Matters [Abstract]
Commitments and Contingencies	Commitments and Contingencies
	Hospira is involved in various claims and legal proceedings, as well as product liability claims, regulatory matters and proceedings related to Hospira's business, including in some instances when Hospira operated as part of Abbott Laboratories.
	Precedex™ Matters
	Hospira is involved in a number of lawsuits relating to the ability of various competitors to market a generic form of Hospira's Precedex™ (dexmedetomidine hydrochloride), a proprietary sedation agent.
	On August 18, 2014, the FDA allowed a carved-out label for generic competitors. Immediately following that decision, Mylan Institutional, LLC and Par Sterile Products, LLC launched generic versions of Precedex™ concentrate. On August 19, 2014, Hospira initiated litigation over the FDA's action, which was settled on October 28, 2014.
	In December 2013, Hospira entered into a settlement agreement in its patent infringement litigation over Precedex™ with Sandoz, Inc. and Sandoz Canada, Inc. (collectively "Sandoz"), related to Sandoz's "Paragraph IV" notice indicating that it has filed an ANDA with the FDA for a generic version of Precedex™. On September 22, 2014, the settlement agreement was amended to allow Sandoz to launch a generic version of Precedex™ in the U.S. from that date and Sandoz subsequently launched a generic version of Precedex™ in the U.S. In February 2015, an ongoing appeal and scheduled oral argument at the U.S. Court of Appeals for the Federal Circuit, stemming from the denial of a motion to intervene by Sun Pharmaceutical Industries, Inc. ("Sun") in the Sandoz patent infringement litigation over Precedex™, was postponed while Hospira and Sun discussed settlement.
	In November 2014, Hospira entered into a confidential settlement agreement in its patent infringement litigation over Precedex™ with Intas Pharmaceuticals Ltd. and Accord Healthcare, Inc. USA (collectively "Intas") related to Intas' "Paragraph IV" notice letter indicating that it has filed an ANDA with the FDA for a generic version of Precedex™. In December 2014, a stipulation of dismissal was filed in U.S. District Court for the Middle District of North Carolina.
	In March 2015, Hospira entered into a confidential settlement agreement in its patent infringement litigation over Precedex™ with Aurobindo Pharma Ltd., Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively "Aurobindo") related to Aurobindo's "Paragraph IV" notice letter indicating that it has filed an ANDA with the FDA for a generic version of Precedex™.
	Hospira and Orion Corporation have ongoing actions against the following parties alleging infringement of US Patent No. 6,716,867:
	Defendant	U.S. District Court Where Filed*
	Sun Pharmaceutical Industries, Inc. and Gland Pharma Ltd.	Eastern District of Michigan, No. 10-cv-14514
	Akorn, Inc.	Northern District of Illinois, No. 14-cv-02811
	Actavis US Holding LLC and Actavis LLC	District of Delaware, No. 14-cv-00488
	Eurohealth International Sarl and West-Ward Pharmaceutical Corp.**	District of Delaware, No. 14-cv-00487
	Eurohealth International Sarl and West-Ward Pharmaceutical Corp.**	District of Delaware, No. 14-cv-01008
	*All filed April 18, 2014, except case No. 10-cv-14514, which was filed November 12, 2010 and case No. 14-cv-01008, which was filed August 1, 2014.
	** Eurohealth International Sarl purchased the assets of Ben Venue Laboratories, Inc. d/b/a Bedford Laboratories. West-    Ward Pharmaceutical Corp. is Eurohealth’s agent in the United States.
	These lawsuits are based on the "Paragraph IV" notice provided by the respective ANDA holders, above, indicating that each has filed an ANDA with the FDA for a generic version of Precedex™. Hospira seeks a judgment of infringement, injunctive relief and costs.
	Stockholder Litigation
	Hospira and members of its Board of Directors are named as defendants in five class action lawsuits filed in the Delaware Court of Chancery alleging breaches of fiduciary duty in connection with the Merger Agreement. Pfizer and Merger Sub are also named as defendants. The lawsuits, which seek to enjoin the proposed transaction, allege generally that the Merger Agreement resulted from an unfair process and fails to maximize value for Hospira stockholders. The lawsuits were filed by the following named plaintiffs, on behalf of themselves and all others similarly situated: Robert J. Casey II, Samuel Montini, Charles Zimmerman, Jason Chen, and Patricia Takach.
	Regulatory Matters
	Hospira's businesses are subject to regulatory inspections by regulatory authorities across the globe. Such regulatory inspections may lead to observations (commonly referred to as Form 483 observations in the U.S.), untitled letters, warning letters or similar correspondence, voluntary or involuntary product recalls, consent decrees, injunctions to halt manufacture and distribution of products, seizures of violative products, import and export bans or restrictions, monetary sanctions, delays in product approvals or clearances, civil penalties, criminal prosecution and other restrictions on operations.
	Hospira has received warning letters from the FDA related to matters affecting its pharmaceutical manufacturing facility in Mulgrave, Victoria, Australia, pharmaceutical and device manufacturing facilities in Clayton and Rocky Mount, North Carolina, its device manufacturing facility in La Aurora de Heredia, Costa Rica, Irungattukottai, India, and its device quality systems and governance in Lake Forest, Illinois. The Company has responded fully, and in a timely manner, to these warning letters. By letter dated April 16, 2015, the FDA advised Hospira that it had completed its evaluation of the Company's corrective actions in response to the April 2010 warning letter relating to Hospira's Rocky Mount and Clayton, North Carolina, pharmaceutical manufacturing facilities. On April 1, 2015, Hospira received a warning letter from the FDA related to a May 2014 inspection of its pharmaceutical manufacturing facility located in Liscate, Italy, to which Hospira has responded.
	The remediation plans in response to the warnings letters involve commitments by Hospira to enhance its quality system, products, facilities, employee training, quality processes and procedures, and technology. While Hospira continues implementing its remediation plans, the plans are subject to update and revision based on issues encountered by Hospira or its third-party consultants during the remediation process, or on further interaction with the FDA or other regulatory bodies. Hospira cannot, however, give any assurances as to the expected date of resolution of the matters identified in the warning letters.
	Litigation Exposure Evaluation
	Hospira's litigation exposure, including product liability claims, is evaluated each reporting period. Hospira's accruals, which are not significant at March 31, 2015 and December 31, 2014, are the best estimate of loss. Based upon information that is currently available, management believes that the likelihood of a material loss in excess of recognized amounts is remote.
	Additional legal proceedings may occur that may result in a change in the estimated accruals recognized by Hospira. It is not feasible to predict the outcome of such proceedings with certainty and there can be no assurance that their ultimate disposition will not have a material adverse effect on Hospira's financial position, cash flows, or results of operations.

Segment_Information

Segment Information	3 Months Ended
	Mar. 31, 2015
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]
Segment Information	Segment Information
	Hospira conducts operations worldwide and is managed in three reportable segments: Americas, EMEA and APAC. The Americas reportable segment includes three operating segments, the U.S., Canada and Latin America; the EMEA reportable segment includes one operating segment, Europe, the Middle East and Africa; and the APAC reportable segment includes two operating segments, Asia and Japan and Australia and New Zealand. In all segments, Hospira sells a broad line of products, including Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals include generic injectables, proprietary specialty injectables and, in certain markets, biosimilars. Medication Management includes infusion pumps, related software and services, dedicated administration sets, gravity administration sets and other device products. Other Pharmaceuticals include large volume I.V. solutions, nutritionals and contract manufacturing.
	Hospira's underlying accounting records are maintained on a legal-entity basis for government and public reporting requirements. Segment disclosures are on a performance basis consistent with internal management reporting. For internal management reporting, intersegment transfers of inventory are recognized at standard cost and are not a measure of segment income from operations. The costs of certain corporate functions, stock-based compensation, Interest expense and Other income, net that benefit the entire organization are not allocated. The following segment information has been prepared in accordance with the internal accounting policies of Hospira, as described in "Part II, Item 8. Financial Statements and Supplementary Data, Note 1" in Hospira's 2014 Form 10-K.
	Reportable segment information:
	The table below presents information about Hospira's reportable segments for the three months ended March 31:
		Net Sales				Income From Operations
	(dollars in millions)	2015		2014		2015			2014
	Americas	$	976.9	$	841.8	$	200		$	141.8
	EMEA	118.5		132.7		(30.5		)	(14.1		)
	APAC	79.5		76.3		16.7			0.9
	Total reportable segments	$	1,174.90	$	1,050.80	186.2			128.6
	Corporate functions					(38.7		)	(18.0		)
	Stock-based compensation					(14.1		)	(11.0		)
	Income From Operations					133.4			99.6
	Interest expense and Other income, net					(11.5		)	(18.5		)
	Income Before Income Taxes					$	121.9		$	81.1

Pfizer_Transaction

Pfizer Transaction	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Pfizer Transaction	Pfizer Transaction
	On February 5, 2015, Hospira entered into the Merger Agreement with Pfizer and Merger Sub. The Merger Agreement provides that, subject to the terms and conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), Merger Sub will merge with and into Hospira with Hospira surviving as a wholly owned subsidiary of Pfizer.
	Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, at the Effective Time, each share of Hospira common stock, par value $0.01 per share, issued and outstanding immediately prior to the Effective Time will be converted into the right to receive $90.00 in cash ("Per Share Merger Consideration"), without interest thereon (other than any shares of Hospira common stock owned by Hospira as treasury stock, any shares owned by Pfizer or its subsidiaries (including Merger Sub), and dissenting shares, if any, which will not be so converted).
	Each Hospira stock option, restricted stock unit, performance share award, performance restricted stock unit and share of restricted stock, whether vested or unvested, that is outstanding immediately prior to the Effective Time will be canceled and converted into the right to receive the Per Share Merger Consideration (in the case of performance share awards and performance restricted stock units, the number of shares of common stock subject to such award will be determined assuming target performance has been met) or, in the case of stock options, the excess, if any, of the Per Share Merger Consideration over the exercise price of such stock option.
	Consummation of the Merger is subject to customary conditions, including, among other things, (i) approval of the holders of a majority of the outstanding shares of Hospira common stock entitled to vote on the Merger, (ii) the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, as well as the expiration or termination of the applicable waiting periods under the antitrust laws of several other jurisdictions, including the E.U., and (iii) the absence of a company material adverse effect on Hospira, as defined in the Merger Agreement.
	The Merger Agreement contains specified termination rights for Pfizer and Hospira, including a mutual termination right in the event that the Merger is not consummated by December 31, 2015, subject to extension to June 30, 2016 under certain circumstances. Hospira must pay Pfizer a $500 million termination fee (the "Termination Fee") in the event the Merger Agreement is terminated by Pfizer following (1) a change of recommendation for the Merger by Hospira’s Board of Directors (the "Board"), (2) the Board’s failure to publicly reaffirm its recommendation within ten business days of a request from Pfizer for reaffirmation following Hospira’s receipt of an acquisition proposal that is publicly announced or publicly known or (3) Hospira’s violation of certain non-solicitation obligations, in each case, as set forth in the Merger Agreement. Hospira also must pay Pfizer the Termination Fee if Hospira terminates the Merger Agreement to enter into a definitive agreement with a third party with respect to a superior proposal (as defined in the Merger Agreement), as set forth in the Merger Agreement. Hospira must also pay Pfizer the Termination Fee if the Merger Agreement is terminated in certain specified circumstances while an acquisition proposal has been publicly made or communicated to the Board and not withdrawn and, within twelve (12) months following such termination, Hospira enters into a definitive agreement with respect to a business combination transaction of the type described in the relevant provisions of the Merger Agreement, or such a transaction is consummated. The Merger Agreement further provides that, upon termination of the Merger Agreement under specified circumstances, Hospira will be required to pay to Pfizer $20 million for expenses incurred or paid by or on behalf of Pfizer (with such expenses paid credited to any Termination Fee subsequently paid by Hospira).
	The Merger Agreement includes restrictions on the conduct of Hospira’s business prior to the completion of the Merger, generally requiring Hospira to conduct its business in the ordinary course and subjecting Hospira to a variety of specified limitations absent Pfizer’s prior written consent.
	During the three months ended March 31, 2015 in connection with the Merger, Hospira incurred $16.2 million of transaction and merger related expenses (legal, advisory, other related fees and integration costs), reported in Selling, general and administrative.

Basis_of_Presentation_and_Sign1

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2015
Basis of Presentation and Significant Accounting Policies [Abstract]
Supplier Advances	Supplier Advances
	Hospira periodically makes supplier advances to achieve timely procurement of products or product components. Supplier advances are in some cases long-term, refundable under certain conditions, either interest bearing or interest free, primarily unsecured and subject to credit risk. In estimating an allowance for loss, Hospira monitors supplier credit, among other factors, and recognizes an allowance in the Condensed Consolidated Statements of Income based on the nature of the advance. Total supplier advances were $33.4 million and $50.9 million as of March 31, 2015 and December 31, 2014, respectively. The current and long-term balances are reported in Prepaid expenses and Other assets, respectively, in the Condensed Consolidated Balance Sheets.
Unapproved Products	Unapproved Products
	Prior to regulatory approval and launch Hospira capitalizes costs associated with certain products. Hospira capitalizes product costs, material and conversion costs in preparation for product launches prior to regulatory approval when regulatory approval of the products is considered probable.

Basis_of_Presentation_and_Sign2

Basis of Presentation and Significant Accounting Policies Basis of Presentation and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2015
Basis of Presentation and Significant Accounting Policies [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]	Hospira is currently evaluating the impact of the following standards on its consolidated financial statements and related disclosures:
	Standard	Description	Effective date of the standard
	ASU 2014-09, Revenue from Contracts with Customers	Supersedes nearly all existing revenue recognition guidance under GAAP. The core principle of the standard is to recognize revenues to depict the transfer of promised goods or services to customers in an amount that reflects the consideration that is expected to be received for those goods or services. The standard defines a five step process to achieve this core principle.	Annual reporting periods beginning after December 15, 2016. Early adoption is not permitted.
			In April 2015, the Financial Accounting Standards Board issued a proposed ASU for a one-year deferral of the effective date of the new revenue recognition standard. If approved, the new standard will become effective for the annual reporting period (including interim periods within those periods) beginning after December 15, 2017 and can be adopted either retrospectively to each prior reporting period presented or as a cumulative effect adjustment as of the date of adoption.
	ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs	Changes the presentation of debt issuance costs in financial statements where an entity presents such costs in the balance sheet as a direct deduction from the related debt liability rather than as an asset. Amortization of the costs is reported as interest expense.	For fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015.
		Hospira's debt issuance costs, net of amortization, as of March 31, 2015 were $13.5 million reported as Other assets.

Business_Acquisition_Business_

Business Acquisition Business Acquisition (Tables)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Schedule of recognized identified assets acquired and liabilities assumed	The following table summarizes the fair value of the assets acquired and liabilities assumed, based on management's best estimate:
	(dollars in millions)
	Current assets, net	$	57.1
	Property and equipment	120.1
	Intangible assets (product rights)	24.6
	IPR&D	3.7
	Goodwill	48.7
	Other non-current assets and liabilities, net	(7.0		)
	Total allocation of purchase price	$	247.2

Restructuring_Actions_Tables

Restructuring Actions (Tables)	3 Months Ended
	Mar. 31, 2015
Restructuring and Related Activities [Abstract]
Aggregate restructuring activity	The following summarizes the aggregate facility optimization and restructuring activity including Device Strategy related restructuring charges, see Note 4, for the three months ended March 31, 2015:
	(dollars in millions)	Employee-Related			Impairment and Accelerated Depreciation Charges			Other		Total
		Benefit Costs
	Balance at January 1, 2015	$	2.8		$	—		$	0.5	$	3.3
	Costs incurred	23.7			5.9			1.5		31.1
	Payments	(1.1		)	—			—		(1.1		)
	Non-cash items	—			(5.9		)	—		(5.9		)
	Balance at March 31, 2015	$	25.4		$	—		$	2	$	27.4

Device_Strategy_Tables

Device Strategy (Tables)	3 Months Ended
	Mar. 31, 2015
Device Strategy [Abstract]
Schedule of Device Strategy and Related Costs	Charges incurred for the Device Strategy, primarily in the Americas segment, were reported as follows:
		Three Months Ended March 31,					Line Item in the
							Condensed Consolidated
	(dollars in millions)	2015			2014		Statement of Income
	Consulting, customer accommodations, contract termination, collection and destruction and other (releases) charges	$	(8.2	)	$	5.6	Cost of products sold
	Inventory (releases) charges	(0.3		)	0.3		Cost of products sold
	Severance and other related costs	17.6			—		Restructuring and impairment
	Other asset impairments and accelerated depreciation	—			0.4		Restructuring and impairment
	Total charges	$	9.1		$	6.3

Investments_Tables

Investments (Tables)	3 Months Ended
	Mar. 31, 2015
Investments [Abstract]
Schedule of combined income statement financial information of unconsolidated equity method investments	Combined income statement financial information of unconsolidated equity method investments is as follows:
		Three Months Ended March 31,
	(dollars in millions)	2015		2014
	Revenue	$	17.3	$	16.3
	Operating expenses	13.8		10.2
	Operating income	3.5		6.1
	Net Income	2.8		4.6

Fair_Value_Measures_Tables

Fair Value Measures (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Basis used to measure certain assets and liabilities at fair value	The following table summarizes the basis used to measure certain assets and liabilities at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
				Fair Value Measurements at Reporting Date, Using:
		March 31,		Quoted Prices		Significant		Significant
				in Active Markets for		Other Observable		Unobservable
				Identical Items		Inputs		Inputs
	(dollars in millions)	2015		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency exchange contracts	$	11.4	$	11.4	$	—	$	—
	Investments	197		2.8		194.2		—
	Interest rate swap contracts	5.2		—		5.2		—
	Financial Liabilities:
	Foreign currency exchange contracts	3.3		—		3.3		—
				Fair Value Measurements at Reporting Date, Using:
		December 31,		Quoted Prices		Significant		Significant
				in Active Markets for		Other Observable		Unobservable
				Identical Items		Inputs		Inputs
	(dollars in millions)	2014		(Level 1)		(Level 2)		(Level 3)
	Financial Assets:
	Foreign currency exchange contracts	$	3	$	3	$	—	$	—
	Investments	194.6		3.7		190.9		—
	Interest rate swap contracts	0.1		—		0.1		—
	Financial Liabilities:
	Foreign currency exchange contracts	0.6		—		0.6		—
Carrying value and fair value of the senior unsecured notes	The carrying value and estimated aggregate fair value, based primarily on market prices (Level 1), of the senior unsecured notes are as follows:
		March 31, 2015				December 31, 2014
	(dollars in millions)	Carrying		Fair Value		Carrying		Fair Value
		Value				Value
	Senior unsecured notes	$	1,750.00	$	2,038.90	$	1,750.00	$	1,924.00

Financial_Instruments_and_Deri1

Financial Instruments and Derivatives (Tables)	3 Months Ended
	Mar. 31, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair value of outstanding derivatives	The following table summarizes Hospira's fair value of outstanding derivatives:
		Condensed Consolidated Balance	March 31,			December 31,
	(dollars in millions)	Sheet Presentation	2015			2014
	Derivatives not designated as hedging instruments
	Foreign currency exchange contracts:	Other receivables	$	11.4		$	3
		Other accrued liabilities	3.3			0.6
	Derivatives designated as hedging instruments
	Interest rate swap contracts:	Other receivables	5.2			0.1
Impact on earnings from derivatives activity	The impact on earnings from derivatives activity was as follows:
		Line Item in the	Three Months Ended March 31,
		Condensed Consolidated
	(dollars in millions)	Statement of Income	2015			2014
	Derivatives not designated as hedging instruments
	Foreign currency exchange contracts	Other income, net	$	(5.0	)	$	(0.7	)
	Derivatives designated as hedging instruments
	Interest rate swap contracts	Interest income	(1.4		)	—

Inventories_Tables

Inventories (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventories	consist of the following:
		March 31,		December 31,
	(dollars in millions)	2015		2014
	Finished products	$	517.3	$	521.7
	Work in process	384.7		324.7
	Materials	279		286.9
	Total	$	1,181.00	$	1,133.30

Property_and_equipment_net_Tab

Property and equipment, net (Tables)	3 Months Ended
	Mar. 31, 2015
Property, Plant and Equipment [Abstract]
Property and equipment, net	Property and equipment, net consists of the following:
		March 31,			December 31,
	(dollars in millions)	2015			2014
	Property and equipment, at cost	$	3,651.80		$	3,607.20
	Accumulated depreciation	(1,799.1		)	(1,790.5		)
	Total Property and equipment, net	$	1,852.70		$	1,816.70

Goodwill_and_Intangible_assets1

Goodwill and Intangible assets, net (Tables)	3 Months Ended
	Mar. 31, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Goodwill and Intangible Assets, Net	The following summarizes Goodwill and Intangible assets, net activity:
	(dollars in millions)	Goodwill			Intangible
					assets, net
	Balance at January 1, 2015	$	1,089.10		$	123.4
	Additions or adjustments	(2.2		)	16.7
	Amortization	—			(11.9		)
	Currency translation effect	(3.0		)	(1.8		)
	Balance at March 31, 2015	$	1,083.90		$	126.4
Schedule of intangible assets, net	Intangible assets, net consist of the following:
		Gross Carrying Amount						Accumulated Amortization						Intangible assets, net
		March 31,			December 31,			March 31,			December 31,			March 31,		December 31,
	(dollars in millions)	2015			2014			2015			2014			2015		2014
	Product rights and other	$	542.4		$	554.3		$	(441.0	)	$	(457.8	)	$	101.4	$	96.5
	Customer relationships	7.2			7.4			(6.6		)	(6.4		)	0.6		1
	IPR&D	4.9			4.9			—			—			4.9		4.9
	Technology	39			39			(19.5		)	(18.0		)	19.5		21
	Total	$	593.5		$	605.6		$	(467.1	)	$	(482.2	)	$	126.4	$	123.4

Other_Assets_Tables

Other Assets (Tables)	3 Months Ended
	Mar. 31, 2015
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Schedule of Other assets	Other assets consist of the following:
		March 31,		December 31,
	(dollars in millions)	2015		2014
	Supplier advances	$	28	$	25.5
	Net investment in sales-type leases, less current portion	4		6.5
	Unapproved products	36.6		36
	Non-current receivables	11		9.2
	All other	48.5		41.8
	Total	$	128.1	$	119

SalesType_Leases_Tables

Sales-Type Leases (Tables)	3 Months Ended
	Mar. 31, 2015
Leases [Abstract]
Net investment in sales-type leases	The net investment in sales-type leases of certain medication management products consists of the following:
			March 31,			December 31,
	(dollars in millions)		2015			2014
	Minimum lease payments receivables		$	10.6		$	13.7
	Unearned interest income		(0.8		)	(1.1		)
	Net investment in sales-type leases		9.8			12.6
	Current portion (1)		(5.8		)	(6.1		)
	Net investment in sales-type leases, less current portion (1)		$	4		$	6.5
	(1)	The current and long-term portions are reported in Trade receivables and Other assets, respectively.

Other_Accrued_Liabilities_Tabl

Other Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Other Accrued Liabilities	Other accrued liabilities consist of the following:
		March 31,		December 31,
	(dollars in millions)	2015		2014
	Accrued rebates	$	126	$	135.5
	Income taxes payable	13.1		3.5
	Product recalls, customer sales allowances, customer accommodations and other related accruals	126.1		127.5
	Accrued returns	26.8		29.1
	All other	305.1		331.2
	Total	$	597.1	$	626.8

PostRetirement_Obligations_and1

Post-Retirement Obligations and Other Long-term Liabilities (Tables)	3 Months Ended
	Mar. 31, 2015
Post-Retirement Obligations and Other Long-term Liabilities [Abstract]
Components of Post-Retirement Obligations and Other Long-Term Liabilities	Post-retirement obligations and other long-term liabilities consist of the following:
		March 31,		December 31,
	(dollars in millions)	2015		2014
	Accrued post-retirement medical and dental costs	$	54.5	$	55.2
	Pension liabilities	88.9		91.9
	Unrecognized tax benefits, including penalties and interest	35.6		33.9
	Product recalls, customer sales allowances, customer accommodations and other related accruals	3.7		31.3
	Accrued returns	12.7		12.7
	All other	34.6		33.7
	Total	$	230	$	258.7

Product_Recalls_Customer_Sales1

Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Summary of product recalls and other related accrual activity	The following summarizes Product recalls, customer sales allowances, customer accommodations and other related accruals activity for the three months ended March 31, 2015:
	(dollars in millions)	Product recalls, customer sales allowances, customer accommodations and other related accruals
	Balances at January 1, 2015	$	158.8
	Provisions net of releases of prior provisions	(11.2		)
	Payments	(17.8		)
	Balances at March 31, 2015	$	129.8

Pension_and_PostRetirement_Ben1

Pension and Post-Retirement Benefits (Tables)	3 Months Ended
	Mar. 31, 2015
Compensation and Retirement Disclosure [Abstract]
Net cost recognized	Net periodic benefit cost recognized for Hospira's pension and post-retirement medical and dental benefit plans consist of the following:
		Pension Plans
			Three Months Ended March 31,
	(dollars in millions)		2015			2014
	Service cost for benefits earned during the period		$	0.6		$	0.4
	Interest cost on projected benefit obligations		6.1			6.5
	Expected return on plans' assets		(7.5		)	(7.8		)
	Amortization of net actuarial losses		4.7			3.1
	Net periodic benefit cost		$	3.9		$	2.2
		Medical and Dental Plans
			Three Months Ended March 31,
	(dollars in millions)		2015			2014
	Interest cost on projected benefit obligations		$	0.6		$	0.6
	Amortization of net actuarial losses		0.2			0.1
	Net periodic benefit cost		$	0.8		$	0.7

Accumulated_Other_Comprehensiv1

Accumulated Other Comprehensive (Loss) Income, net of tax (Tables)	3 Months Ended
	Mar. 31, 2015
Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]
Accumulated other comprehensive (loss) income, net of taxes	Changes in Accumulated Other Comprehensive Loss, net of taxes consists of the following:
	(dollars in millions)		Cumulative Foreign Currency Translation Adjustments(1)			Cumulative Retirement Plans Unrealized Losses(2)			Cumulative Unrealized (Losses) on Investments(3)			Cumulative Losses on			Total Accumulated Other Comprehensive Loss
												Terminated Cash Flow Hedges(4)
	Balance at January 1, 2015		$	(228.8	)	$	(132.3	)	$	(4.2	)	$	(1.6	)	$	(366.9	)
	Other comprehensive (loss) income before reclassifications		(67.7		)	—			1.5			—			(66.2		)
	Amounts Reclassified from		—			3.9			—			0.1			4
	Accumulated Other Comprehensive Loss
	Balance at March 31, 2015		$	(296.5	)	$	(128.4	)	$	(2.7	)	$	(1.5	)	$	(429.1	)
	(1)	Net of taxes of $0.0 million as of March 31, 2015 and December 31, 2014.
	(2)	Net of taxes of $76.9 million and $77.9 million as of March 31, 2015 and December 31, 2014, respectively.
	(3)	Net of taxes of $2.2 million and $3.4 million as of March 31, 2015 and December 31, 2014, respectively.
	(4)	Net of taxes of $1.1 million as of March 31, 2015 and December 31, 2014.
Schedule of reclassifications out of accumulated other comprehensive loss	The following summarizes reclassifications out of Accumulated Other Comprehensive Loss:
			Three Months Ended March 31,
	(dollars in millions)		2015			2014			Line Item in the
									Condensed Consolidated
									Statement of Income
	Amortization of loss on terminated cash flow hedges		$	0.1		$	—		Other income, net
			—			—			Income tax expense
	Net of income taxes		0.1			—
	Amortization of pension plans actuarial losses		4.7			3.1			(1)
	Amortization of medical and dental plans actuarial losses		0.2			0.1			(1)
	Total amortization before income taxes		4.9			3.2
			(1.0		)	(1.5		)	Income tax expense
	Net of income taxes		3.9			1.7
	Total reclassifications for the period		$	4		$	1.7
	(1)	These Accumulated Other Comprehensive Loss components are included in the computation of net periodic benefit cost. See Note 17 for additional details.

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2015
Earnings Per Share [Abstract]
Disclosure of basic and diluted earnings per share and effect of stock-based awards on the weighted average number of shares outstanding used in calculating diluted earnings per share	The following table shows the effect of stock-based awards on the weighted average number of shares outstanding used in calculating Diluted Earnings Per Share, and the number of shares excluded from the Diluted Earnings Per Share calculation as the exercise price of the awards exceeded the average stock price:
		Three Months Ended March 31,
	(shares in millions)	2015	2014
	Weighted average basic common shares outstanding	171.4	166.5
	Incremental shares outstanding related to stock-based awards	3.7	1.9
	Weighted average dilutive common shares outstanding	175.1	168.4
	Outstanding awards for which the exercise price of the award exceeds the average stock price	0.3	5.1

Incentive_Stock_Program_Tables

Incentive Stock Program (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation Expense	Stock-based compensation expense associated with Hospira's 2004 Plan consists of the following:
		Three Months Ended March 31,
	(dollars in millions)	2015			2014
	Stock-based compensation expense	$	14.1		$	11
	Income tax benefit recognized	5.1			4
Weighted average fair value and weighted average assumptions utilized for option grants	he weighted average grant date fair value using the Black-Scholes option-pricing model, and the corresponding weighted average assumptions were as follows:
		Three Months Ended March 31,
		2014
	Expected volatility	27.7		%
	Expected life (years)	4.7
	Risk-free interest rate	1.5		%
	Expected dividend yield	0		%
	Fair value per stock option	$	11.26
Weighted fair value and weighted average assumptions for the performance share award grants	he weighted average grant date fair value using the Monte Carlo simulation model and the corresponding weighted average assumptions were as follows:
		Three Months Ended March 31,
		2014
	Expected volatility	30.8		%
	Risk-free interest rate	0.6		%
	Expected dividend yield	0		%
	Fair value per performance share	$	54.55

Segment_Information_Tables

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting, Disclosure of Other Information about Entity's Reportable Segments [Abstract]
Information about Hospira's reportable segments	The table below presents information about Hospira's reportable segments for the three months ended March 31:
		Net Sales				Income From Operations
	(dollars in millions)	2015		2014		2015			2014
	Americas	$	976.9	$	841.8	$	200		$	141.8
	EMEA	118.5		132.7		(30.5		)	(14.1		)
	APAC	79.5		76.3		16.7			0.9
	Total reportable segments	$	1,174.90	$	1,050.80	186.2			128.6
	Corporate functions					(38.7		)	(18.0		)
	Stock-based compensation					(14.1		)	(11.0		)
	Income From Operations					133.4			99.6
	Interest expense and Other income, net					(11.5		)	(18.5		)
	Income Before Income Taxes					$	121.9		$	81.1

Basis_of_Presentation_and_Sign3

Basis of Presentation and Significant Accounting Policies (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Basis of Presentation and Significant Accounting Policies [Abstract]
Debt issuance cost	$13.50
Advances to supplier	33.4	50.9
Unapproved Products	52.7	52.5
Unapproved Product Reserves	$6.80	$7.60

Business_Acquisition_Details

Business Acquisition (Details) (USD $)	0 Months Ended	3 Months Ended
In Millions, unless otherwise specified	Jul. 04, 2014	Mar. 31, 2015	Mar. 31, 2014	Feb. 28, 2014
				product
API Busines
Business Acquisition [Line Items]
Preliminary purchase price	$247.20
Portion of purchase price, subject to eighteen month hold-back	17
Acquisition and integration-related costs		0.5	0.9
Cumulative acquisition and integration-related costs		$40.10
Evolabis
Business Acquisition [Line Items]
Number of on-market oncology products added				15

Business_Acquisition_Assets_Ac

Business Acquisition (Assets Acquired and Liabilities Assumed) (Details) (USD $)	0 Months Ended
In Millions, unless otherwise specified	Jul. 04, 2014	Mar. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Goodwill		$1,083.90	$1,089.10
API Busines
Business Acquisition [Line Items]
Current assets, net	57.1
Property and equipment	120.1
Intangible assets (product rights)	24.6
IPR&D	3.7
Goodwill	48.7
Other non-current assets and liabilities, net	-7
Total allocation of purchase price	247.2
Product Rights | API Busines
Business Acquisition [Line Items]
Weighted average useful life	9 years

Restructuring_Actions_Details

Restructuring Actions (Details) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Restructuring Reserve
Asset impairment charges	$1.80	$0
Restructuring Charges	31.1
Restructuring and related cost, incurred	0.6	0.3
Employee Severance
Restructuring Reserve
Restructuring costs incurred to date	15.9
Contract Termination
Restructuring Reserve
Restructuring costs incurred to date	2.3
Restructuring and Impairment | Boulder, Colorado | API R&D | Employee Related and Other Exit Costs
Restructuring Reserve
Business exit costs	0.7
Asset impairment charges	1.8
Restructuring and Impairment | Americas | Clayton, North Carolina, Manufacturing Facility | Other Restructuring
Restructuring Reserve
Restructuring Charges	10.4
Restructuring, Impairment And (Gain) On Disposal Of Assets, Net | Americas | Clayton, North Carolina, Manufacturing Facility | Facility Closing
Restructuring Reserve
Asset impairment charges			21.9
Restructuring Charges			45
Forecast | Americas | Clayton, North Carolina, Manufacturing Facility | Employee Severance
Restructuring Reserve
Expected cost remaining	15
Forecast | Americas | Clayton, North Carolina, Manufacturing Facility | Other Restructuring
Restructuring Reserve
Expected cost remaining	$8

Restructuring_Actions_Details_

Restructuring Actions (Details 2) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Restructuring Reserve [Roll Forward]
Balance at January 1, 2015	$3.30
Costs incurred	31.1
Payments	-1.1
Non-cash items	-5.9
Balance at March 31, 2015	27.4
Employee-Related Benefit Costs
Restructuring Reserve [Roll Forward]
Balance at January 1, 2015	2.8
Costs incurred	23.7
Payments	-1.1
Non-cash items	0
Balance at March 31, 2015	25.4
Impairment and Accelerated Depreciation Charges
Restructuring Reserve [Roll Forward]
Balance at January 1, 2015	0
Costs incurred	5.9
Payments	0
Non-cash items	-5.9
Balance at March 31, 2015	0
Other
Restructuring Reserve [Roll Forward]
Balance at January 1, 2015	0.5
Costs incurred	1.5
Payments	0
Non-cash items	0
Balance at March 31, 2015	$2

Device_Strategy_Details

Device Strategy (Details) (Device Strategy, USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cost of Products Sold | Consulting, customer accommodations, contract termination, collection and destruction and other (releases) charges
Device Strategy and Related Costs [Line Items]
Charges incurred	($8.20)	$5.60
Cost of Products Sold | Inventory (releases) charges
Device Strategy and Related Costs [Line Items]
Charges incurred	-0.3	0.3
Restructuring and Impairment | Severance and other related costs
Device Strategy and Related Costs [Line Items]
Charges incurred	17.6	0
Restructuring and Impairment | Other asset impairments and accelerated depreciation
Device Strategy and Related Costs [Line Items]
Charges incurred	0	0.4
Americas
Device Strategy and Related Costs [Line Items]
Charges incurred	$9.10	$6.30

Collaborative_Arrangements_Det

Collaborative Arrangements (Details) (USD $)	3 Months Ended		18 Months Ended	0 Months Ended	1 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Sep. 30, 2014	Apr. 29, 2013	Mar. 31, 2015	Apr. 30, 2013	Dec. 31, 2014
Schedule of Collaborative Arrangement Agreements [Line Items]
Research and development expense	$135,400,000	$83,200,000
Cumulative development funding			90,900,000
NovaQuest
Schedule of Collaborative Arrangement Agreements [Line Items]
Number of biosimilar products in an agreement				3
Research and development expense	2,900,000	6,900,000		50,000,000
Milestone payments contingent on sale of product						20,000,000
Maximum | NovaQuest
Schedule of Collaborative Arrangement Agreements [Line Items]
Development funding to be contributed						120,000,000
Collaborative Arrangement | Pfenex
Schedule of Collaborative Arrangement Agreements [Line Items]
Payment for collaborative arrangement development funding					51,000,000
Collaborative arrangement development funding to be contributed, development milestones	31,000,000				31,000,000
Collaborative arrangement development funding to be contributed, additional contribution	260,000,000				260,000,000
Collaborative arrangement development funding to be contributed, period of contribution	5 years
Development funding to be contributed by another party in arrangement	20,000,000				20,000,000
Development funding to be contributed							55,000,000
Collaborative arrangement development funding paid and capitalized	$17,800,000
Collaborative Arrangement | Q Core
Schedule of Collaborative Arrangement Agreements [Line Items]
Number of years in payment agreement	2 years

Investments_Details

Investments (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Jul. 31, 2014	Sep. 30, 2014
Equity method investments
Equity income from affiliates, net	$1,600,000	$3,300,000
Combined income statement information of unconsolidated equity method investments
Revenue	1,174,900,000	1,050,800,000
Operating income	133,400,000	99,600,000
Net Income	75,600,000	67,900,000
Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax	2,700,000		4,200,000
Zydus Hospira Oncology Private Limited
Equity method investments
Ownership in a joint venture, Zydus Hospira Oncology Private Limited (as a percent)	50.00%
Unconsolidated equity method investments
Combined income statement information of unconsolidated equity method investments
Revenue	17,300,000	16,300,000
Operating expenses	13,800,000	10,200,000
Operating income	3,500,000	6,100,000
Net Income	2,800,000	4,600,000
R&D Venture
Combined income statement information of unconsolidated equity method investments
Advances to affiliate				30,000,000
Additional advances within 12 months				15,000,000
Convertible Bond Due September 30, 2019 | Convertible Debt
Combined income statement information of unconsolidated equity method investments
Face amount					$200,000,000
Interest rate	6.00%

Fair_Value_Measures_Details

Fair Value Measures (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Fair Value Assets and Liabilities Measurement
Senior unsecured notes, carrying value	$1,750	$1,750
Senior unsecured notes, fair value	2,038.90	1,924
Fair Value, Measurements, Recurring
Fair Value Assets and Liabilities Measurement
Foreign currency exchange contracts	11.4	3
Investments	197	194.6
Interest rate swap contracts	5.2	0.1
Foreign currency exchange contracts	3.3	0.6
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Items (Level 1)
Fair Value Assets and Liabilities Measurement
Foreign currency exchange contracts	11.4	3
Investments	2.8	3.7
Interest rate swap contracts	0	0
Foreign currency exchange contracts	0	0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Fair Value Assets and Liabilities Measurement
Foreign currency exchange contracts	0	0
Investments	194.2	190.9
Interest rate swap contracts	5.2	0.1
Foreign currency exchange contracts	3.3	0.6
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Fair Value Assets and Liabilities Measurement
Foreign currency exchange contracts	0	0
Investments	0	0
Interest rate swap contracts	0	0
Foreign currency exchange contracts	$0	$0

Financial_Instruments_and_Deri2

Financial Instruments and Derivatives (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Derivatives not designated as hedging instruments | Foreign currency forward exchange contracts | Other receivables
Derivatives, Fair Value
Derivative asset	$11.40	$3
Derivatives not designated as hedging instruments | Foreign currency forward exchange contracts | Other accrued liabilities
Derivatives, Fair Value
Derivative liability	3.3	0.6
Derivatives designated as hedging instruments | Interest rate swap contracts: | Other receivables
Derivatives, Fair Value
Derivative liability	$5.20	$0.10

Financial_Instruments_and_Deri3

Financial Instruments and Derivatives (Details 2) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Derivatives not designated as hedging instruments | Foreign currency forward exchange contracts | Other income, net
Derivative Instruments, Loss (Gain)
Line Item in the Condensed Consolidated Statement of Income	($5)	($0.70)
Derivatives designated as hedging instruments | Interest rate swap contracts: | Interest Income
Derivative Instruments, Loss (Gain)
Line Item in the Condensed Consolidated Statement of Income	($1.40)	$0

Inventories_Details

Inventories (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Inventory Disclosure [Abstract]
Finished products	$517.30	$521.70
Work in process	384.7	324.7
Materials	279	286.9
Total inventories	1,181	1,133.30
Inventory Reserves	$126	$136.40

Property_and_equipment_net_Det

Property and equipment, net (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Property, Plant and Equipment [Abstract]
Property and equipment, at cost	$3,651.80	$3,607.20
Less: accumulated depreciation	-1,799.10	-1,790.50
Total property and equipment, net	$1,852.70	$1,816.70

Goodwill_and_Intangible_assets2

Goodwill and Intangible assets, net (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Goodwill
Balance at January 1, 2015	$1,089.10
Additions or adjustments	-2.2
Currency translation effect	-3
Balance at March 31, 2015	1,083.90
Intangible assets, net
Balance at January 1, 2015	123.4
Additions or adjustments	16.7
Amortization	-11.9	-21.8
Currency translation effect	-1.8
Balance at March 31, 2015	$126.40

Goodwill_and_Intangible_assets3

Goodwill and Intangible assets, net (Details 2) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014
Intangible Assets:
Finite-lived intangible assets, amortization expense	$11.90	$21.80
Estimated intangible asset amortization for 2015	44.9
Estimated intangible asset amortization for 2016	24.1
Estimated intangible asset amortization for 2017	17.2
Estimated intangible asset amortization for 2018	7.8
Estimated intangible asset amortization for 2019	5
Gross Carrying Amount	593.5		605.6
Accumulated Amortization	-467.1		-482.2
Net Intangible Assets	126.4		123.4
IPR&D
Intangible Assets:
Gross Carrying Amount	4.9		4.9
Accumulated Amortization	0		0
Net Intangible Assets	4.9		4.9
Product rights and other
Intangible Assets:
Gross Carrying Amount	542.4		554.3
Accumulated Amortization	-441		-457.8
Net Intangible Assets	101.4		96.5
Customer relationships
Intangible Assets:
Gross Carrying Amount	7.2		7.4
Accumulated Amortization	-6.6		-6.4
Net Intangible Assets	0.6		1
Technology
Intangible Assets:
Gross Carrying Amount	39		39
Accumulated Amortization	-19.5		-18
Net Intangible Assets	$19.50		$21
Minimum
Intangible Assets:
Useful lives of intangible assets (in years)	1 year
Maximum
Intangible Assets:
Useful lives of intangible assets (in years)	12 years
Weighted Average
Intangible Assets:
Useful lives of intangible assets (in years)	9 years

Other_Assets_Details

Other Assets (Details) (USD $)	Mar. 31, 2015		Dec. 31, 2014
In Millions, unless otherwise specified
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Supplier advances	$28		$25.50
Net investment in sales-type leases, less current portion	4	[1]	6.5	[1]
Unapproved products	36.6		36
Non-current receivables	11		9.2
All other	48.5		41.8
Total	$128.10		$119
[1]	The current and long-term portions are reported in Trade receivables and Other assets, respectively.

SalesType_Leases_Details

Sales-Type Leases (Details) (USD $)	3 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015		Dec. 31, 2014
Net investment in sales-type leases
Minimum lease payments receivable	$10.60		$13.70
Unearned interest income	-0.8		-1.1
Net investment in sales-type leases	9.8		12.6
Current portion	-5.8	[1]	-6.1	[1]
Net investment in sales-type leases, less current portion	$4	[1]	$6.50	[1]
Number of days amount past due in sales-type leases	90 days		90 days
[1]	The current and long-term portions are reported in Trade receivables and Other assets, respectively.

Other_Accrued_Liabilities_Deta

Other Accrued Liabilities (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Payables and Accruals [Abstract]
Accrued rebates	$126	$135.50
Income taxes payable	13.1	3.5
Product recalls, customer sales allowances, customer accommodations and other related accruals	126.1	127.5
Accrued returns	26.8	29.1
All other	305.1	331.2
Total	$597.10	$626.80

PostRetirement_Obligations_and2

Post-Retirement Obligations and Other Long-term Liabilities (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Post-Retirement Obligations and Other Long-term Liabilities [Abstract]
Accrued post-retirement medical and dental costs	$54.50	$55.20
Pension liabilities	88.9	91.9
Unrecognized tax benefits, including penalties and interest	35.6	33.9
Product recalls, customer sales allowances, customer accommodations and other related accruals	3.7	31.3
Accrued returns	12.7	12.7
All other	34.6	33.7
Total	$230	$258.70

Product_Recalls_Customer_Sales2

Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals (Textual) (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Millions, unless otherwise specified
Payables and Accruals [Abstract]
Product recall and other related accruals	$129.80	$158.80

Product_Recalls_Customer_Sales3

Product Recalls, Customer Sales Allowances, Customer Accommodations and Other Related Accruals (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Product Recalls and Related Accruals [Roll Forward]
Balances at January 1, 2015	$158.80
Provisions net of releases of prior provisions	-11.2
Payments	-17.8
Balances at March 31, 2015	$129.80

Pension_and_PostRetirement_Ben2

Pension and Post-Retirement Benefits (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Defined Benefit Plan Disclosure
Defined contribution plan expenses	$11.10	$11.60
Pension Plans
Defined Benefit Plan Disclosure
Service cost for benefits earned during the period	0.6	0.4
Interest cost on projected benefit obligations	6.1	6.5
Expected return on plans' assets	-7.5	-7.8
Amortization of net actuarial losses	4.7	3.1
Net periodic benefit cost	3.9	2.2
Medical and Dental Plans
Defined Benefit Plan Disclosure
Interest cost on projected benefit obligations	0.6	0.6
Amortization of net actuarial losses	0.2	0.1
Net periodic benefit cost	$0.80	$0.70

Shortterm_Borrowings_and_Longt1

Short-term Borrowings and Long-term Debt (Details) (Unsecured Revolving Credit Facility Due October, 2016, USD $)	Mar. 31, 2015
Unsecured Revolving Credit Facility Due October, 2016
Long-term and Short-term Debt Instruments [Line Items]
Maximum borrowing capacity	$1,000,000,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Unrecognized tax benefits, estimated future decreases resulting from settlements with taxing authorities in next fiscal year	$10,000,000

Shareholders_Equity_Details

Shareholders' Equity (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014	Apr. 30, 2011
Common and Preferred Stock
Common stock authorized (shares)	400,000,000
Common stock par value (in dollars per share)	$0.01
Preferred stock authorized (shares)	50,000,000
Preferred stock par value (in dollars per share)	$0.01
Common stock issued (shares)	185,800,000	183,600,000
Common stock outstanding (shares)	172,600,000	170,400,000
Treasury Stock
Treasury Stock, repurchase authorization (in dollars)	$0		$1,000,000,000
Prior Repurchases
Treasury Stock
Treasury Stock, repurchase authorization (in dollars)	$800,000,000

Accumulated_Other_Comprehensiv2

Accumulated Other Comprehensive (Loss) Income, net of tax (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015		Mar. 31, 2014		Dec. 31, 2014
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]
Balance at January 1, 2015	($366.90)
Other comprehensive (loss) income before reclassifications	-66.2
Amounts Reclassified from Accumulated Other Comprehensive Loss	4
Balance at March 31, 2015	-429.1
Cumulative foreign currency translation adjustments, tax	0				0
Cumulative retirement plans unrealized losses, tax	76.9				77.9
Cumulative Unrealized (Losses) on Investments, tax	2.2				3.4
Cumulative unrealized gains on marketable equity securities, tax	1.1				1.1
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]
Income tax (benefit) expense	-47.9		-16.5
Net Income	75.6		67.9
Cumulative Foreign Currency Translation Adjustments
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]
Balance at January 1, 2015	-228.8	[1]
Other comprehensive (loss) income before reclassifications	-67.7	[1]
Amounts Reclassified from Accumulated Other Comprehensive Loss	0	[1]
Balance at March 31, 2015	-296.5	[1]
Cumulative Retirement Plans Unrealized Losses
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]
Balance at January 1, 2015	-132.3	[2]
Other comprehensive (loss) income before reclassifications	0	[2]
Amounts Reclassified from Accumulated Other Comprehensive Loss	3.9	[2]
Balance at March 31, 2015	-128.4	[2]
Cumulative Unrealized Gains on Marketable Equity Securities
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]
Balance at January 1, 2015	-4.2	[1]
Other comprehensive (loss) income before reclassifications	1.5	[1]
Amounts Reclassified from Accumulated Other Comprehensive Loss	0	[1]
Balance at March 31, 2015	-2.7	[1]
Cumulative Gains on Terminated Cash Flow Hedges
Reclassification Out of Accumulated Other Comprehensive Loss [Roll Forward]
Balance at January 1, 2015	-1.6	[3]
Other comprehensive (loss) income before reclassifications	0	[3]
Amounts Reclassified from Accumulated Other Comprehensive Loss	0.1	[3]
Balance at March 31, 2015	-1.5	[3]
Reclassification out of Accumulated Other Comprehensive Income
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]
Net Income	4		1.7
Reclassification out of Accumulated Other Comprehensive Income | Cumulative Retirement Plans Unrealized Losses
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]
Income tax (benefit) expense	-1		-1.5
Amortization of pension plans actuarial losses	4.7	[4]	3.1	[4]
Amortization of medical and dental plans actuarial losses	0.2	[4]	0.1	[4]
Total amortization before income taxes	4.9		3.2
Net Income	3.9		1.7
Reclassification out of Accumulated Other Comprehensive Income | Cumulative Gains on Terminated Cash Flow Hedges
Reclassifications Out of Accumulated Other Comprehensive Loss [Abstract]
Amortization of loss on terminated cash flow hedges	0.1		0
Income tax (benefit) expense	0		0
Net Income	$0.10		$0
[1]	Net of taxes of $0.0 million as of MarchB 31, 2015 and DecemberB 31, 2014.
[2]	Net of taxes of $76.9 million and $77.9 million as of MarchB 31, 2015 and DecemberB 31, 2014, respectively
[3]	Net of taxes of $1.1 million as of MarchB 31, 2015 and DecemberB 31, 2014.
[4]	These Accumulated Other Comprehensive Loss components are included in the computation of net periodic benefit cost. See Note 17 for additional details.

Earnings_Per_Share_Details

Earnings Per Share (Details)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted average basic common shares outstanding (shares)	171.4	166.5
Incremental shares outstanding related to stock-based awards (shares)	3.7	1.9
Weighted average dilutive common shares outstanding (shares)	175.1	168.4
Outstanding Stock Awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Outstanding options with exercise price of the options exceeding the average stock price (in shares)	0.3	5.1

Incentive_Stock_Program_Detail

Incentive Stock Program (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award
Stock-based compensation expense	$14.10	$11
Unrecognized compensation costs related to non-vested share-based compensation arrangements	118.5
Period over which unrecognized compensation cost is expected to be recognized (in years)	1 year 11 months
2004 Long Term Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award
Stock-based compensation expense	14.1	11
Income tax benefit recognized	$5.10	$4

Incentive_Stock_Program_Detail1

Incentive Stock Program (Details 2) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2015	Sep. 30, 2013
Stock option award
Weighted average fair value and weighted average assumptions
Volatility (percent)	27.70%
Expected life (in years)	4 years 8 months 12 days
Risk-free interest rate (percent)	1.50%
Dividend yield (percent)	0.00%
Fair value per stock option (usd per share)	$11.26
Performance stock awards
Weighted average fair value and weighted average assumptions
Volatility (percent)	30.80%
Risk-free interest rate (percent)	0.60%
Dividend yield (percent)	0.00%
Fair value per stock option (usd per share)	$54.55
Restricted stock awards
Restricted Stock and Performance Share Awards
Granted (in shares)		800,000
Weighted average grant date fair value, at the end of the period (in dollars per share)		$87.51	$42.74

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (Merger Agreement by and Among Hospira, Pfizer and Merger Sub)	3 Months Ended
	Mar. 31, 2015
	Lawsuit
Merger Agreement by and Among Hospira, Pfizer and Merger Sub
Loss Contingencies
Number of lawsuits	5

Segment_Information_Details

Segment Information (Details) (USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
	Segment
Segment Reporting Information
Reportable segments number	3
Net Sales	$1,174.90	$1,050.80
Stock-based compensation	-14.1	-11
Income From Operations	133.4	99.6
Interest expense and Other expense, net	-11.5	-18.5
Income Before Income Taxes	121.9	81.1
Americas
Segment Reporting Information
Operating units number	3
Net Sales	976.9	841.8
Income From Operations	200	141.8
EMEA
Segment Reporting Information
Operating units number	1
Net Sales	118.5	132.7
Income From Operations	-30.5	-14.1
APAC
Segment Reporting Information
Operating units number	2
Net Sales	79.5	76.3
Income From Operations	16.7	0.9
Operating segments
Segment Reporting Information
Net Sales	1,174.90	1,050.80
Income From Operations	186.2	128.6
Corporate functions
Segment Reporting Information
Income From Operations	($38.70)	($18)

Pfizer_Transaction_Details

Pfizer Transaction (Details) (USD $)	0 Months Ended	3 Months Ended
	Feb. 05, 2015	Mar. 31, 2015	Feb. 05, 2015
Business Acquisition [Line Items]
Common stock par value (in dollars per share)		$0.01
Merger agrement with Pfizer Inc. and Perkins Holding Company (Merger Agreement)
Business Acquisition [Line Items]
Common stock par value (in dollars per share)	$0.01		$0.01
Cash consideration for each share converted	$90		$90
Merger agreement, termination fee	500,000,000
Merger agreement, number of days to reaffirm recommendation by board of directors	10 days
Merger agreement, termination related expenses	20,000,000
Merger related expenses		$16,200,000